Xiangkai Meng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiangkai Meng has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Guangyong Jin
Changchun University of Science and Technology, Changchun, China
1 shared publication - Han Zhang
Tumor Etiology and Screening Department of Cancer Institute and General Surgery, Key Laboratory of Cancer Etiology and Prevention in Liaoning Education Department, and Key Laboratory of Gastrointestinal Cancer Etiology and Prevention in Liaoning Province, The First Hospital of China Medical University, Shenyang, People’s Republic of China
1 shared publication - Hao Li
Department of Clinical Laboratory, The First Affiliated Hospital of China Medical University, Shenyang, People’s Republic of China
1 shared publication - Liping Sun
Tumor Etiology and Screening Department of Cancer Institute and General Surgery, Key Laboratory of Cancer Etiology and Prevention in Liaoning Education Department, and Key Laboratory of Gastrointestinal Cancer Etiology and Prevention in Liaoning Province, The First Hospital of China Medical University, Shenyang, People’s Republic of China
1 shared publication Luyang Duanmu
Changchun Univ. of Science and Technology (China)
1 shared publication- Ping Gong
Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China
1 shared publication
Latest Publications
- Open Access
- 4 November 2021
- Published by Springer Nature in Cancer Cell International
- Vol. 21 (1) , 1-19
Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response
Background: The prognosis of high grade serous ovarian cancer (HGSOC) patients is closely related to the immune microenvironment and immune response. Based on this, the purpose of this study was to construct a model to predict chemosensitivity and prognosis, and provide novel biomarkers for immunotherapy and prognosis evaluation of HGSOC. Methods: GSE40595 (38 samples), GSE18520 (63 samples), GSE26712 (195 samples), TCGA (321 samples) and GTEx (88 samples) were integrated to screen differential expressed genes (DEGs) of HGSOC. The prognosis related DEGs (DEPGs) were screened through overall survival analysis. The DEGs-encoded protein–protein interaction network was constructed and hub genes of DEPGs (DEPHGs) were generated by STRING. Immune characteristics of the samples were judged by ssGSEA, ESTIMATE and CYBERSORT. TIMER was used to analyze the relationship between DEPHGs and tumor-infiltrating immunocytes, as well as the immune checkpoint genes, finally immune-related DEPHGs (IDEPHGs) were determined, and whose expression in 12 pairs of HGSOC tissues and tumor-adjacent tissues were analyzed by histological verification. Furthermore, the chemosensitivity genes in IDEPHGs were screened according to GSE15622 (n = 65). Finally, two prediction models of paclitaxel sensitivity score (PTX score) and carboplatin sensitivity score (CBP score) were constructed by lasso algorithm. The area under curve was calculated to estimate the accuracy of candidate gene models in evaluating chemotherapy sensitivity. Results: 491 DEGs were screened and 37 DEGs were identified as DEPGs, and 11 DEPHGs were further identified. Among them, CXCL13, IDO1, PI3, SPP1 and TRIM22 were screened as IDEPHGs and verified in the human tissues. Further analysis showed that IDO1, PI3 and TRIM22 could independently affect the chemotherapy sensitivity of HGSOC patients. The PTX score was significantly better than TRIM22, PI3, SPP1, IDO1 and CXCL13 in predicting paclitaxel sensitivity, so was CBP score in predicting carboplatin sensitivity. What’s more, both of the HGSOC patients with high PTX score or high CBP score had longer survival time. Conclusions: Five IDEPHGs identified through comprehensive bioinformatics analysis were closely related with the prognosis, immune microenvironment and chemotherapy sensitivity of HGSOC. Two prediction models based on IDEPHGs might have potential application of chemotherapy sensitivity and prognosis for patients with HGSOC.
- 4 November 2021
- Published by Springer Nature in Cancer Cell International
- Vol. 21 (1) , 1-19
Open AccessModel constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response
Background: The prognosis of high grade serous ovarian cancer (HGSOC) patients is closely related to the immune microenvironment and immune response. Based on this, the purpose of this study was to construct a model to predict chemosensitivity and prognosis, and provide novel biomarkers for immunotherapy and prognosis evaluation of HGSOC. Methods: GSE40595 (38 samples), GSE18520 (63 samples), GSE26712 (195 samples), TCGA (321 samples) and GTEx (88 samples) were integrated to screen differential expressed genes (DEGs) of HGSOC. The prognosis related DEGs (DEPGs) were screened through overall survival analysis. The DEGs-encoded protein–protein interaction network was constructed and hub genes of DEPGs (DEPHGs) were generated by STRING. Immune characteristics of the samples were judged by ssGSEA, ESTIMATE and CYBERSORT. TIMER was used to analyze the relationship between DEPHGs and tumor-infiltrating immunocytes, as well as the immune checkpoint genes, finally immune-related DEPHGs (IDEPHGs) were determined, and whose expression in 12 pairs of HGSOC tissues and tumor-adjacent tissues were analyzed by histological verification. Furthermore, the chemosensitivity genes in IDEPHGs were screened according to GSE15622 (n = 65). Finally, two prediction models of paclitaxel sensitivity score (PTX score) and carboplatin sensitivity score (CBP score) were constructed by lasso algorithm. The area under curve was calculated to estimate the accuracy of candidate gene models in evaluating chemotherapy sensitivity. Results: 491 DEGs were screened and 37 DEGs were identified as DEPGs, and 11 DEPHGs were further identified. Among them, CXCL13, IDO1, PI3, SPP1 and TRIM22 were screened as IDEPHGs and verified in the human tissues. Further analysis showed that IDO1, PI3 and TRIM22 could independently affect the chemotherapy sensitivity of HGSOC patients. The PTX score was significantly better than TRIM22, PI3, SPP1, IDO1 and CXCL13 in predicting paclitaxel sensitivity, so was CBP score in predicting carboplatin sensitivity. What’s more, both of the HGSOC patients with high PTX score or high CBP score had longer survival time. Conclusions: Five IDEPHGs identified through comprehensive bioinformatics analysis were closely related with the prognosis, immune microenvironment and chemotherapy sensitivity of HGSOC. Two prediction models based on IDEPHGs might have potential application of chemotherapy sensitivity and prognosis for patients with HGSOC.
- 4 December 2020
- Published by SPIE-Intl Soc Optical Eng
- Vol. 11617, 1161710-52
Research on diagnostic system integrated nucleic acid extraction and detection
With the continuous impact of COVID-19, the demand for rapid genetic diagnosing at the inspection and quarantine site, emergency treatment of sudden infectious diseases and clinical in vitro diagnosis was increasing rapidly. In order to achieve rapid, automatic nucleic acid extraction and detection, an automatic diagnostic system which integrates nucleic acid extraction, amplification and biochip fluorescence detection is designed. The diagnostic system designed based on multidisciplinary intersection of biology, optoelectronics, machinery and computer technology. At first, the nucleic acid extraction part has 1-8 sample flux and uses the principle of the silicon filter can adsorb nucleic acid at different pH to achieve nucleic acid extraction. After the extraction process, the nucleic acid is injected into biochip through robotic arm. There is a specific microarray reaction chamber on the chip, which can be combined with a specific biological substance; Secondly the amplification part used the principle of flat-plate PCR to achieve nucleic acid amplification in the biochip; After amplification, the nucleic acid detection realized under the irradiation of the excitation light at 530nm, the specificity target on the biochip will emit light, thus the fluorescence image scanned by COMS camera and the result analyzed by the software on PC; At last device control, automation and detection of the integrated device realized by the STM32 single-chip microcomputer and CAN communication method to establish a device communication network. The diagnostic system will automate workflow, and provides a result that reports on the detection and interpretation of targets in the samples. The imaging module resolution was less than 10 microns/pixel. The CV value of the sample was less than 10%. The results provide that the diagnostic system can provide more accurate and more automated equipment for nucleic acid extraction, amplification and detection.
- 4 December 2020
- Published by SPIE-Intl Soc Optical Eng
- Vol. 11617, 1161710-52
Research on diagnostic system integrated nucleic acid extraction and detection
With the continuous impact of COVID-19, the demand for rapid genetic diagnosing at the inspection and quarantine site, emergency treatment of sudden infectious diseases and clinical in vitro diagnosis was increasing rapidly. In order to achieve rapid, automatic nucleic acid extraction and detection, an automatic diagnostic system which integrates nucleic acid extraction, amplification and biochip fluorescence detection is designed. The diagnostic system designed based on multidisciplinary intersection of biology, optoelectronics, machinery and computer technology. At first, the nucleic acid extraction part has 1-8 sample flux and uses the principle of the silicon filter can adsorb nucleic acid at different pH to achieve nucleic acid extraction. After the extraction process, the nucleic acid is injected into biochip through robotic arm. There is a specific microarray reaction chamber on the chip, which can be combined with a specific biological substance; Secondly the amplification part used the principle of flat-plate PCR to achieve nucleic acid amplification in the biochip; After amplification, the nucleic acid detection realized under the irradiation of the excitation light at 530nm, the specificity target on the biochip will emit light, thus the fluorescence image scanned by COMS camera and the result analyzed by the software on PC; At last device control, automation and detection of the integrated device realized by the STM32 single-chip microcomputer and CAN communication method to establish a device communication network. The diagnostic system will automate workflow, and provides a result that reports on the detection and interpretation of targets in the samples. The imaging module resolution was less than 10 microns/pixel. The CV value of the sample was less than 10%. The results provide that the diagnostic system can provide more accurate and more automated equipment for nucleic acid extraction, amplification and detection.